Authors

• Maja Strozzi — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0003-4596-8261

Abstract

Pulmonary arterial hypertension (PAH) is a severe chronic, progressive disease. It affects the group of patients with congenital heart diseases (CHD); a high-profile example is Eisenmenger’s syndrome, the CHD with the greatest mortality and morbidity. Advanced PAH treatment for adult congenital heart diseases (ACHD) has significantly improved the outcome and clinical course for these patients, and endothelin receptor antagonist, primarily bosentan, are recommended as first-line treatment today. All case studies and registries show that bosentan improved the exercise tolerance, reduced pulmonary vascular resistance, and decreased the mortality of these patients. Other advanced therapy drugs (phosphodiesterase inhibitors and prostaglandins) are added in case of disease progression. Advanced PAH therapy can be administered long-term with good results and few side effects. Apart from Eisenmenger’s syndrome, other patients from the PAH group in ACHD can be treated through advanced therapy. In the treatment of surgical patients with ACHD who have developed or are developing a subsequent PAH, a different double endothelin inhibitor is indicated, macitentan. Therapy through a combination of drugs has not led to any further significant improvements in relation to treatment by a monotherapy of endothelin receptor inhibitors. It is possible that patients with Fontan circulation will be the target group for the treatment with these drugs.

Keywords

pulmonary arterial hypertension, adult congenital heart defects, Eisenmenger’s syndrome, advanced pulmonary hypertension treatment, endothelin receptor antagonist

DOI

Full Text

## Introduction Pulmonary hypertension (PH) is defined as increased median pressure in the pulmonary artery above 25 mmHg. The definition of pulmonary arterial hypertension (PAH) includes, in addition to PH, pulmonary capillary pressure lower than 15 mmHg and pulmonary vascular resistance (PVR) higher than 3 Wood units. These definitions do not include the possibility of PH occurring during heart load. (1) Pulmonary hypertension is a chronic, progressive disease which is the result of the damage of the pulmonary arterial endothelium, causing release of the mediators that stimulate the multiplication and migration of smooth muscle cells, which in turn causes gradual obliteration of the arterial lumen. (2) The incidence of PAH in patients with adult congenital heart diseases (ACHD) is different in different registries, but it is usually around 6-11%. (3) The incidence increases with the age of the patient (CONOR registry). (4) ## Pulmonary arterial hypertension in adults with congenital heart diseases According to the conclusions of the latest global Pulmonary Hypertension Symposium in 2013, PAH in ACHD can be divided into four sub-groups (5): [list-style:upper-alpha] 1. Eisenmenger’s syndrome 2. Significant left-to-right (L-R) shunt Operable Inoperable (6) 3. PAH with a coincidental finding of a congenital heart disease 4. Postoperative PAH (corrected defect) Pulmonary vascular resistance (PVR), together with PAH, is very important in ACHD. Patients with a L-R shunt have a high pulmonary flow, can have high PAH and a still acceptable PVR, and surgical intervention is possible for these patients despite PAH. On the other hand, patients with a low pulmonary flow in Fontan circulation can develop PVR without PAH. (7) There is a significant difference between PAH caused by congenital heart disease and idiopathic PAH; it has a more benign course in ACHD. This is caused firstly by the morphology of the right ventricle which adapts to the high pressure and later leads to heart failure. Although the pressures in the lungs are extremely high, shunts act as a “safety valve”, protecting the right ventricle, at the cost of cyanosis and limited exertion capacity, but the survival is significantly longer compared with PAH of a different etiology. PAH treatment is limited. Supportive therapy includes oral anticoagulants, diuretics, oxygen therapy, in some cases digitalis, and when anemia needs to be treated, iron supplements. Calcium antagonists, although still recommended in guidelines, have not proven to be very effective in treating PAH. Targeted advanced therapy is the only one that has an effect on the clinical improvement and prolongation of life in patients with PAH, with reversibility tests not being crucial to the decision of implementing it. ## Advanced therapy Advanced therapy of PAH includes three types of medication which affect the reduction of vasoconstriction or stimulate vasodilation and have an anti-proliferative effect. These are (8): [list-style:upper-alpha] 1. Prostacyclin derivatives 2. Phosphodiesterase inhibitors 3. Endothelin receptor antagonists **Prostacyclin derivatives** are powerful vasodilators and smooth muscle cell proliferation inhibitors, and affect the activity of thromboxane A2. They are administered intravenously or through inhalation. Their positive effect on hemodynamics and PAH symptoms has been proven, but they are unsuitable for long-term use due to toxicity and side effects. Today they are most widely used as the “third line” in case of deterioration together with other advanced medication, and prior to heart and lungs transplantation. (9) Nitrous oxide (NO) is a powerful vasodilator and thrombocyte and smooth muscle cell proliferation inhibitor. In PAH, NO production is significantly decreased, which causes vasoconstriction and cell proliferation. By preventing cyclic guanosine monophosphate (cGMP) activation, phosphodiesterase inhibitors (PDE-5) stimulate vasodilation and reduce smooth muscle cell proliferation. In all studies and registries, sildenafil had a positive effect on quality of life, especially on the improvement of the 6-minute walk test. Other PDE-5 inhibitors had a similar effect. Today they are most often used when endothelin receptor antagonists are ineffective or in a combination with them in case of disease progression, but can be administered as the first medication for PAH in ACHD. (10) Endothelin receptor antagonists are the newest medication for the treatment of PAH in ACHD. Their effectiveness is based on publications that have established that endothelin values are significantly higher in patients with CHD-PAH, and that their values increase significantly between the right ventricle and the pulmonary veins, i.e. in pulmonary circulation. (11) The first medication from this group, bosentan, has proven to be effective in small series or registries, which has made randomized studies possible. (12) The outcomes of these studies have made these medications the first choice for treatment of PAH in ACHD. ## Eisenmenger’s Syndrome Eisenmenger’s Syndrome (ES) was named after the Austrian doctor who first described it in the late 19th century, and its pathophysiology was defined and clinically described in detail by P. Wood in the mid-20th century. This syndrome is defined by a severe pulmonary hypertension connected with congenital heart disease, i.e. a left-to-right shunt which has in time turned into right-to-left shunt and led to chronic cyanosis with an effect on multiple organ systems. It is clinically characterized by exertion intolerance, dyspnea, and cyanosis, and in the long term by arrhythmia and sudden death as well as heart failure and hemoptysis. Life expectancy for these patients is significantly reduced, and exertion tolerance is extremely low. Survival depends on the degree of cyanosis, exertion tolerance (usually determined through a 6-minute walk test), the degree of cardiac compensation, and the dynamics of the symptom progression. (13) The decision to introduce advanced therapy is based on the 6-minute walk test score of less than 350 m and arterial O2 saturation below 85%. New York Heart Association (NYHA) class is not crucial for the decision, but the most often included patients are those from NYHA III. (14) The first-choice medication, according to recommendations, is bosentan, while all the rest are second-line choices. ## Use of bosentan in the treatment of pulmonary arterial hypertension in Eisenmenger’s syndrome The first randomized study with BREATHE-5 bosentan was conducted on patients with ES. (15) It included stabile patients over the age of 12, in the third functional class, with a 6-minute walk test distance of 150-450 m. The study included 54 patients randomized 2:1 into groups receiving the medication and placebo. The primary aim was to study the changes in oxygen saturation in a resting as well as changes to PVR after 16-week treatment. The secondary aim included following changes in hemodynamic parameters, 6-minute walk tests, and functional class. The study results indicated that after 16 weeks of bosentan therapy, patients with ES show no decrease in oxygen saturation, their exertion tolerance in the 6-minute walk test is significantly improved (+53.1 m, P=0.008), and PVR is reduced (-472 dyn.sec.cm-5, P=0.04), with satisfactory medication safety. Administration of the medication was continued for patients in the BREATHE-5 open-label extension study, and the results consistently indicated further improvements in the patients who continued with the medication, as well as significant improvement of the patients in the placebo group. (16) Medication safety was good. A slight and insignificant hemoglobin decrease was reported. More serious side effects reported include a 10% increase of transaminase, so monitoring is required during treatment, which should be terminated in case the increase was >8-fold or if there are clinical signs of liver insufficiency. Treatment duration quickly became an important question. The results from the registries monitoring patients undergoing bosentan therapy are cause for optimism. Long-term bosentan treatment over a period of 6 years achieved a significant decrease in the values of pro brain-type natriuretic peptide (proBNP) and a significant mortality reduction (17) and the existing improvements in the 6-minute walk test as well as improvement of the functional class over the 8-year monitoring period remain constant, with a slight further improvement for some of the patients. (17, 18) ## Treatment of pulmonary arterial hypertension for other groups of patients with adult congenital heart disease 1. Pulmonary arterial hypertension in congenital heart disease with a significant L-R shunt The decision to close the shunt is based on estimating whether the surgical intervention will prevent PAH progression, improve long-term prognosis, or improve symptoms. Once a significant PVR is established, surgical intervention can be risky. Patients with a PVR up to 2 are considered to be operable, and those with >8 Wood/m2 inoperable. An individual assessment at a tertiary center is required in the case of PVR of 4-8 Wood/m2. There is no clear proof that advanced therapy helps patients with PVR become eligible for corrective surgical intervention, but it can be conducted individually. 1. Pulmonary arterial hypertension with accidentally discovered congenital heart disease This condition is treated like idiopathic PAH. 1. Advanced therapy in postoperative PAH In these cases the patient has undergone CHD correction, but the PAH is still present or can continue to increase despite total correction; for some patients it is increased due to residual defects or as a side effect of an earlier surgical intervention. Endothelin receptor inhibitors, primarily macitentan, are the first line of advanced therapy for those patients. ## Use of macitentan in the treatment of pulmonary arterial hypertension in adult congenital heart disease Macitentan, a double endothelin inhibitor, was proven effective in the SERAPHIN study (19) whose primary goal was to monitor “time to disease progression”. This term is increasingly used in other, later studies among patients with ACHD, but it must be clearly defined. In the SERAPHIN study it related to the time of appearance of one of the following events: death, atrial septostomy, lung transplant, introduction of prostanoids, and other signs of disease deterioration. The secondary aim of the study was monitoring of the changes in the 6-minute walk test, functional class, cause of death, and, understandably, the safety of the treatment during the 6-month monitoring. The results of the study showed that macitentan significantly reduces the risk of morbidity and mortality: 45% RR (P< 0.0001) for a 10 mg per day dose, and 30% RR (P=0.0108) for a 3 mg dose. (19) Macitentan was particularly effective in patients who had not previously undergone advanced therapy as compared to placebo patients (a 37 m increase of walk distance for the 6-minute walk test for the group taking 10 mg dose per day, P<0.01). It is interesting to note that patients with worse functional class (III/IV) improved much more as a result of the treatment. ## Combined treatment Combined advanced therapy with both bosentan and sildenafil was tested on patients with PAH and ACHD. The monitored parameters were the 6-minute walk test and PVR. Patients receiving bosentan therapy and the combined bosentan and sildenafil therapy showed significant improvement when compared to placebo, but the combined therapy showed no statistically significant difference compared with bosentan monotherapy. (20) Introducing the second (phosphodiesterase inhibitors) or third line (prostacyclin) of advanced therapy is recommended in case of further disease deterioration. ## Advanced therapy in patients with Fontan circulation Patients with Fontan circulation are characterized by the absence of the sub-pulmonary ventricle. Due to this, increased PVR significantly effects the hemodynamic fall (“falling Fontan”), since the flow in the arterioles adversely affects the maintenance of the pulmonary flow. (21) The reason for increased PVR despite PAH absence is probably the combination of the lung flow prior to the operation, i.e. postoperative non-pulsatile blood flow that likely affects the decreased stimulation to the creation of microcirculation, production of NO and prostacyclin disruption, and negative remodeling and endothelium dysfunction. (22) Introducing advanced therapy on patients with Fontan circulation is based on administering of prostaglandin (iloprost) to a group of patients with significant hemodynamic deterioration, which achieved improvement of the maximum oxygen consumption (+1.3 ml/kg/min, P=0.04) within that group of patients. (23) Currently a study (TEMPO) is under way which tests the administering of bosentan to stable patients with Fontan circulation, monitoring the effect of the medication on the physical exertion, hemodynamics, and changes to the functional class. (24) ## Conclusion Treatment of pulmonary arterial hypertension has been significantly improved by the introduction of new medication, which affect the reduction of vasoconstriction or stimulate vasodilation in pulmonary circulation and which have an anti-proliferative effect. Around one tenth of the patients with ACHD develop PAH, and advanced therapy that can be administered long-term has a significant effect on clinical improvement (functional NYHA class decrease, increase in walking distance) while also prolonging life expectancy.

Literature

1. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25) Suppl:D42–50. https://doi.org/10.1016/j.jacc.2013.10.032
2. Rabinovitch M. It all begins with EVE (endogenous vascular elastase). Isr J Med Sci. 1996;32:803-8. https://pubmed.ncbi.nlm.nih.gov/8950241/
3. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thilén U, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J. 2005;26(21):2325–33. https://doi.org/10.1093/eurheartj/ehi396
4. van Riel AC, Schuuring MJ, van Hessen ID, Zwinderman AH, Cozijnsen L, Reichert CL, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014;174(2):299–305. https://doi.org/10.1016/j.ijcard.2014.04.072
5. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25) Suppl:D34–41. https://doi.org/10.1016/j.jacc.2013.10.029
6. Galič N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–537. https://doi.org/10.1093/eurheartj/ehp297
7. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. 2014;35(11):691–700. https://doi.org/10.1093/eurheartj/eht437
8. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–36. https://doi.org/10.1056/NEJMra040291
9. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866–70. https://doi.org/10.1056/NEJM200006223422503
10. Tay EL, Papaphylactou M, Diller GP, Alonso-Gonzalez R, Inuzuka R, Giannakoulas G, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol. 2011;149(3):372–6. https://doi.org/10.1016/j.ijcard.2010.02.020
11. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation. 1991 Dec;84(6):2280–5. https://doi.org/10.1161/01.CIR.84.6.2280
12. Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol. 2005;98(1):147–51. https://doi.org/10.1016/j.ijcard.2004.08.025
13. Kempny A, Dimopoulos K, Alonso-Gonzalez R, Alvarez-Barredo M, Tutarel O, Uebing A, et al. Six-minute walk test distance and resting oxygen saturations but not functional class predict outcome in adult patients with Eisenmenger syndrome. Int J Cardiol. 2013;168:4784–9. https://doi.org/10.1016/j.ijcard.2013.07.227
14. D’Alto M, Diller GP. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart. 2014;100:1322–8. https://doi.org/10.1136/heartjnl-2014-305574
15. Galič N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48–54. https://doi.org/10.1161/CIRCULATIONAHA.106.630715
16. Gatzoulis MA, Beghetti M, Galič N, Granton J, Berger RM, Lauer A, et al. BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127:27–32. https://doi.org/10.1016/j.ijcard.2007.04.078
17. Diller GP, Alonso-Gonzalez R, Kempny A, Dimopoulos K, Inuzuka R, Giannakoulas G, et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart. 2012;98(9):736–42. https://doi.org/10.1136/heartjnl-2011-301522
18. Diller GP, Alonso-Gonzalez R, Dimopoulos K, Alvarez-Barredo M, Koo C, Kempny A, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol. 2013;167:840–7. https://doi.org/10.1016/j.ijcard.2012.02.007
19. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galič N, Ghofrani HA, et al. SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18. https://doi.org/10.1056/NEJMoa1213917
20. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sřndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124–31. https://doi.org/10.1093/eurheartj/ehq011
21. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681–7. https://doi.org/10.1093/eurheartj/ehn215
22. Presson RG, Baumgartner WA, Peterson AJ, Glenny RW, Wagner WW. Pulmonary capillaries are recruited during pulsatile flow. J Appl Physiol (1985). 2002;92(3):1183–90. https://doi.org/10.1152/japplphysiol.00845.2001
23. Rhodes J, Ubeda-Tikkanen A, Clair M, Fernandes SM, Graham DA, Milliren CE, et al. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol. 2013;168:2435–40. https://doi.org/10.1016/j.ijcard.2013.03.014
24. Hebert A, Jensen AS, Idorn L, Sřrensen KE, Sřndergaard L. The effect of bosentan on exercise capacity in Fontan patients; rationale and design for the TEMPO study. BMC Cardiovasc Disord. 2013 May 11;13:36. https://doi.org/10.1186/1471-2261-13-36